Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 5/20 | 0.39 |
| ▸ | PARP2 | Q9UGN5 | 3/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 6/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 6/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 6/20 | 0.36 |
| ▸ | TYK2 | P29597 | 8/20 | 0.34 |
| ▸ | DHODH | Q02127 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27354943 | 0.92 | PARP1 (0.43) | PARP1PARP2DHODH | |
| SCHEMBL21227401 | 0.89 | TYK2 (0.37) | TYK2 | |
| SCHEMBL27354747 | 0.85 | PARP1 (0.39) | PARP1PARP2CHRM2CHRM1CHRM3 | |
| SCHEMBL20594635 | 0.81 | KDM4E (0.42) | TYK2DHODH | |
| SCHEMBL20697405 | 0.80 | TYK2 (0.43) | PARP1PARP2TYK2DHODH | |
| SCHEMBL20689398 | 0.80 | TYK2 (0.43) | PARP1PARP2TYK2DHODH | |
| SCHEMBL27354759 | 0.79 | DHODH (0.35) | PARP1PARP2CHRM2CHRM1CHRM3 | |
| SCHEMBL22498188 | 0.78 | KDM4E (0.47) | PARP1 | |
| SCHEMBL21947985 | 0.78 | TYK2 (0.46) | PARP1PARP2TYK2 | |
| SCHEMBL21258634 | 0.78 | KDM4E (0.33) | TYK2DHODH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260062416-A1 | INHIBITORS OF KIF18A AND USES THEREOF | ACCENT THERAPEUTICS INC (US) | 2026-03-05 | — | — | US | disclosed |
| WO-2024035950-A1 | INHIBITORS OF KIF18A AND USES THEREOF | ACCENT THERAPEUTICS, INC. (US) | 2024-02-15 | — | — | WO | disclosed |
| WO-2024035950-A1 | INHIBITORS OF KIF18A AND USES THEREOF | ACCENT THERAPEUTICS, INC. (US) | 2024-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260062416-A1 | INHIBITORS OF KIF18A AND USES THEREOF | KIF18A, KIF18B, KIF5B | PARP1 873/4885PARP2 1076/4885CHRM2 3385/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.